PROTEINURIC KIDNEY DISEASE
Clinical trials for PROTEINURIC KIDNEY DISEASE explained in plain language.
Never miss a new study
Get alerted when new PROTEINURIC KIDNEY DISEASE trials appear
Sign up with your email to follow new studies for PROTEINURIC KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to protect kidneys in High-Risk genetic group
Disease control Recruiting nowThis study is testing an investigational drug called VX-147 for people with kidney disease caused by specific changes in the APOL1 gene. It aims to see if the drug can reduce protein loss in urine and slow the decline of kidney function over 48 weeks. The study will enroll about …
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 04, 2026 03:36 UTC
-
Experimental drug targets genetic cause of kidney damage
Disease control Recruiting nowThis study is testing whether an investigational drug called MZE829 is safe and can reduce protein leakage from the kidneys in adults with chronic kidney disease who have a specific high-risk genetic type (APOL1). The trial will enroll about 56 participants to take the drug for 1…
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE2 • Sponsor: Maze Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 03:34 UTC
-
New drug trial targets genetic cause of kidney damage
Disease control Recruiting nowThis study is testing an investigational drug called Inaxaplin for people with a specific genetic form of kidney disease (APOL1-mediated). The main goal is to see if the drug safely reduces the amount of protein leaking into the urine, which is a key sign of kidney damage. The tr…
Matched conditions: PROTEINURIC KIDNEY DISEASE
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC